A recent study found that adalimumab biosimilars were as effective as the adalimumab originator in treating psoriasis. The study analyzed data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and concluded that the biosimilars are viable alternatives, supporting the potential cost savings and improved patient access to treatment. The study also highlighted the need for further research with larger sample sizes and the importance of considering detailed baseline covariates to reduce bias.

Source: JAMA Dermatology